Patient-Reported Outcomes from the Positive Phase 3 monarchE Trial for Verzenio® at St. Gallen Virtual Congress 2021
The Pharma Data
MARCH 17, 2021
This analysis revealed the addition of Verzenio to ET did not result in a clinically meaningful difference in patients reporting being bothered by treatment side effects. Tolaney, MD, MPH, Harvard Medical School, Dana-Farber Cancer Institute. Overall, patient compliance for PROs was greater than 90 percent.
52 
Let's personalize your content